FSRH

Contents

Ab	brevia	itions us	ed	iii		
Gr	Grading of recommendations					
Lis	List of tables					
Ex	ecutiv	e summ	ary of recommendations	viii		
Re	sourc	es		x		
1	Purpose and scope			1		
2	Definitions of overweight and obesity			2		
3	Why is this guideline focusing on contraception and raised BMI needed?			2		
4	An overview of data on fertility, sexual activity, contraceptive use and unintended pregnancy among women with raised BMI					
5	Suita	Suitability of contraceptive methods for women who are overweight or women with obesity				
	5.1	Intraut	erine contraception (IUC)	6		
		5.1.1	IUC effectiveness	6		
		5.1.2	IUC safety	7		
		5.1.3	Weight gain with IUC	8		
		5.1.4	Health benefits of IUC	8		
		5.1.5	Practical considerations with IUC	8		
	5.2	Progestogen-only implants (IMP)		8		
		5.2.1	Implant effectiveness	9		
		5.2.2	Implant safety	11		
		5.2.3	Weight gain with implants	11		
		5.2.4	Health benefits of implants	11		
		5.2.5	Practical considerations with implants	11		
	5.3	Progestogen-only injectable		12		
		5.3.1	DMPA effectiveness	12		
		5.3.2	DMPA safety	13		
		5.3.3	Weight gain with DMPA	14		
		5.3.4	Health benefits of DMPA	15		
		5.3.5	Practical considerations with DMPA	15		

FSRH guideline: Overweight, Obesity and Contraception

FSRH				
5.4	Progestogen-only pill (POP)			
	5.4.1	POP effectiveness	15	
	5.4.2	POP safety	16	
	5.4.3	Weight gain with POP	17	
	5.4.4	Health benefits of POP	17	
5.5	Combined hormonal contraception (CHC)		17	
	5.5.1	CHC effectiveness	17	
	5.5.2	CHC safety	20	
	5.5.3	Weight gain with CHC	22	
	5.5.4	Health benefits of CHC	22	
5.6	Barrier methods of contraception		22	
	5.6.1	Barrier method effectiveness	22	
	5.6.2	Barrier method safety	22	
5.7	Fertility awareness methods			
5.8	Emergency contraception (EC)		23	
	5.8.1	Cu-IUD	23	
	5.8.2	Oral EC	23	
5.9	Female surgical sterilisation		25	
	5.9.1	Effectiveness and safety	25	
Cont	raception and weight management treatment		25	
6.1	Weight-loss medication and contraception		25	
	6.1.1	Orlistat	26	
	6.1.2	Liraglutide	26	
	6.1.3	Naltrexone/buproprion	27	
	6.1.4	Laxatives	27	
6.2	Weight-loss surgery and contraception		27	
	6.2.1	Background	27	
	6.2.2	UKMEC information on bariatric surgery	28	
	6.2.3	Effectiveness and safety of contraception after bariatric surgery	29	
	6.2.4	Contraception before bariatric surgery	31	

6

7 Assessed to be a few bold in contract of the first	\FSRH		
7 Approach to issues of weight in contraceptive consultations	32		
Recommendations for future research			
Considerations for implementation of this guideline			
Useful links	33		
References	34		
Appendix 1: FSRH Clinical Guideline Development Process			
Questions for continuing professional development			
Auditable outcomes			
Comments and feedback on published guideline	58		

Information Box

Title	Overweight, Obesity and Contraception
Author/Publisher	Faculty of Sexual & Reproductive Healthcare
Publication date	April 2019
Superseded document	None
Review date	April 2024
Available online	www.fsrh.org/documents/fsrh-clinical-guidance-overweight-and-obesity-april-2019